Revenue segments as reported by the company.

Consumer Health

Pharmaceutical

Medical Devices

Innovative Medicine

MedTech

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, marketing and administrative expenses

Research and development expense

In-process research and development

Interest expense

Other expense

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Johnson & Johnson

Band-Aid is a brand name of American pharmaceutical and medical devices giant Johnson & Johnson's line of adhesive bandages.

Band-Aid

Johnson's Baby is an American brand of baby cosmetics and skin care products owned by Johnson & Johnson. The brand dates back to 1893 when Johnson's Baby Powder was introduced. Product line consists of baby powder, shampoos, body lotions, massage oil, shower gels and baby wipes. The brand has reputation for making baby products that are "exceptionally pure and safe" since at least the 1980s.

Johnson's Baby

Aveeno is a brand of skin care and hair care products in the United States owned by American consumer goods and pharmaceutical company Johnson & Johnson. Aveeno was founded in 1945, and its first product was their Soothing Bath Treatment. The active ingredient in all Aveeno products are colloidal oats and/or oat extracts - Avenanthramides, which have been branded as "active naturals". Aveeno offers products to treat skin conditions such as eczema, psoriasis, urushiol-induced contact dermatitis, pruritus ani, chickenpox, hives, and sunburn.

Aveeno

Neutrogena is an American brand of skin care, hair care and cosmetics, that is headquartered in Los Angeles, California. According to product advertising at their website, Neutrogena products are distributed in more than 70 countries. Neutrogena was founded in 1930 by Emanuel Stolaroff, and was originally a cosmetics company named Natone. It is now part of the US-based Johnson & Johnson conglomerate, which bought the independent company in 1994.

Neutrogena

Clean & Clear is a line of dermatology products owned by Johnson & Johnson.

Clean & Clear

Listerine is a brand of antiseptic mouthwash product. It is promoted with the slogan "Kills germs that cause bad breath". Named after Joseph Lister, a pioneer of antiseptic surgery, Listerine was developed in 1879 by Joseph Lawrence, a chemist in St. Louis, Missouri.

Listerine

Acuvue (from "Accurate view") is a brand of disposable contact lenses made by Jacksonville-based Vistakon, a subsidiary of Johnson & Johnson (J&J).

Acuvue

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Johnson & Johnson reports solid Q4 earnings, eyes $60B Pharma revenue

Johnson & Johnson's Q4 2022 showed steady operational growth and strong financial performance. The company aims for continued growth in Pharmaceuticals, focusing on key products and pipeline advancements. Challenges include managing costs, addressing sales declines, and navigating market uncertainties.

Johnson & Johnson reports resilient Q1 performance amidst challenges

Johnson & Johnson's Q1 2023 performance reflects resilience and growth across key segments despite short-term challenges.
The company's strategic focus on innovation, resource management, and portfolio diversification positions it for future success.
While facing legal and financial headwinds, Johnson & Johnson remains optimistic about its outlook for 2023 and beyond.
Increased guidance, product developments, and commitment to safety and innovation underscore the company's long-term growth potential.

Johnson & Johnson reports strong Q2 earnings and strategic growth plans

Johnson & Johnson showcased robust financial results in Q2, raising full-year guidance and highlighting growth in MedTech and Pharmaceuticals. Despite challenges from pricing pressures and litigation, the company remains focused on strategic opportunities and maintaining a strong market position. With a clear focus on innovation and growth, Johnson & Johnson is poised for continued success in the healthcare sector.

Johnson & Johnson posts strong Q3 results amidst growth strategies

Johnson & Johnson (JNJ) delivered robust Q3 results, showcasing growth in sales, earnings, and operational efficiency across key segments, positioning the company for future success.
While facing challenges from geopolitical factors, legal issues, and upcoming competition, JNJ's strategic strengths in acquisitions, innovation, and market presence offer avenues for sustained growth.
With a focus on key brands, pipeline advancements, and MedTech innovations, JNJ remains poised to meet revenue targets, navigate challenges, and capitalize on market opportunities in the coming years.

Johnson & Johnson reports robust 2023 performance and strategic growth outlook

Johnson & Johnson's strong 2023 performance in Innovative Medicine and MedTech drove operational sales growth. Despite inflationary pressures impacting margins, JNJ remains focused on enhancing shareholder returns and pursuing strategic M&A deals. Opportunities for growth in 2024 include new product launches and advancements in key focus areas.

Johnson & Johnson posts strong Q1 earnings, eyes growth opportunities

Johnson & Johnson's Q1 2024 earnings reflect solid performance across key segments, with a focus on innovation and strategic growth initiatives.
Despite challenges in certain segments, the company's proactive approach to restructuring and market dynamics positions it for future success.
Opportunities in Vision Care, Pulmonary Hypertension, and Orthopaedics underscore potential for sustained growth and market leadership.
Overall, Johnson & Johnson's diversified product portfolio and financial outlook support confidence in achieving growth targets for 2024.

Johnson & Johnson posts strong Q2 results, eyes growth opportunities

Johnson & Johnson delivered a robust performance in Q2 2024, driven by strong sales growth in both Innovative Medicine and MedTech segments, supported by strategic initiatives.
While facing challenges in certain markets and the need for continued innovation, the company's outlook remains positive with a solid guidance for the full year 2024.
By capitalizing on opportunities in key products and markets, Johnson & Johnson is well-positioned to navigate challenges and drive sustainable growth in the healthcare sector.

Johnson & Johnson reports robust Q3 earnings amidst legal challenges

Johnson & Johnson's Q3 2024 earnings call showcased strong financial performance, driven by growth in key segments and successful product launches. Despite facing challenges with talc litigation, the company remains focused on innovation, capital allocation, and resolving legal issues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Fortis

Dividend Aristocrats represent a wide range of stocks in different industries, but each of these companies holds one characteristic in common: their management teams have raised their dividend distributions each year for more than 25 years.

2 Great Dividend Aristocrats to Buy in November

Amgen

Amazon

Boeing

Cisco Systems

Chevron

Dow Inc

Intel

Coca-Cola

Merck

Microsoft

NIKE

Procter & Gamble

Verizon

"The Dow® [adds a stock] if the company has an excellent reputation,

Buy 3 November Dogs Of The Dow And Watch 7 More

TAIPEI and SAN DIEGO , Nov. 1, 2024 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and infectious diseases, today announced the appointment of Dr. Yiu-Lian Fong to the board of directors for Ding Li Development Ltd.  Dr. Fong, a present member of the Bio Taiwan Committee (BTC) under the Executive Yuan since 2020, has served various organizations in Taiwan including the BTC, the Ministry of Science and Technology Council, and the Medical Device Innovation Center, NCKU as an expert consultant since 2017 to help drive the growth of Biotech industry.

Senhwa Biosciences Announces the Appointment of Dr. Yiu-Lian Fong, the Former Global Head of Janssen Diagnostic Innovation and R&D at Johnson & Johnson as the New Corporate Director

A greater number of patients treated with subcutaneous TREMFYA® induction and maintenance achieved clinical and endoscopic remission at 48 weeks in the Phase 3 GRAVITI study versus placebo TREMFYA ® could become the first IL-23 treatment to offer both a subcutaneous and intravenous (IV) induction regimen for patients living with Crohn's disease (CD), pending FDA approval PHILADELPHIA , Oct. 28, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced results from the Phase 3 GRAVITI study of TREMFYA® (guselkumab), the first and only IL-23 inhibitor, demonstrating robust results in subcutaneous (SC) induction and maintenance therapy. The findings demonstrated significant clinical remission and endoscopic response at 48 weeks in adults with moderately to severely active CD.1 These results are among the 14 Johnson & Johnson abstracts presented at the American College of Gastroenterology (ACG) 2024, October 25-30.

TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to demonstrate robust results with a fully subcutaneous regimen in both induction and maintenance in Crohn's disease

AbbVie

Abbott Labs

These healthcare stocks have fantastic dividend track records.

3 Dividend Growth Stocks You Can Buy and Hold Forever

First-of-its-kind Phase 3b study shows TREMFYA ® achieved statistical significance across all primary and secondary endpoints in low body surface area psoriasis with special site involvement Johnson & Johnson launches library of clinical images from Phase 3b VISIBLE study to enhance clinical decision making for people across all skin tones living with moderate to severe plaque psoriasis LAS VEGAS , Oct. 25, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announced today that treatment with TREMFYA® (guselkumab) resulted in clear or almost clear skin in the majority of adults with low body surface area (BSA) moderate plaque psoriasis (PsO) with special site involvement who had failed topical treatment. Sensitive or highly visible areas affected by PsO, including the scalp, face, skin folds and genitals, are considered "special sites" and can have significant impact on patients' daily lives, yet systemic treatment is infrequently provided and this group of patients remains largely undertreated.1 Data from the Phase 3b SPECTREM study, the first prospective, large-scale, randomized-controlled, double-blind clinical study to measure skin clearance and other treatment outcomes in low BSA moderate PsO with involvement across four special sites (scalp, face, skin folds and genitals) and previous topical treatment failure, were presented today at the 2024 Fall Clinical Dermatology Conference.

New SPECTREM study findings reveal TREMFYA® (guselkumab) effectively clears overlooked and undertreated plaque psoriasis

Apple

Brookfield Renewable Partners

Blackrock Inc

New Linde PLC

Realty Income Corp

I have added Brookfield Renewable Partners and Linde to The Dividend Income Accelerator Portfolio, increasing the portfolio's allocation to the Materials and the Utilities Sectors. After their inclusions, the portfolio's Weighted Average Dividend Yield [TTM] stands at 4.32% and its 5-Year Weighted Average Dividend Growth Rate [CAGR] at 7.25%. Berkshire Hathaway (accounting for 6.58% of the portfolio), BlackRock (4.48%), Apple (4.30%), Johnson & Johnson (4.00%) and Realty Income (3.91%) represent the largest positions of our dividend portfolio.

Two Strategic Dividend Picks: One For Dividend Income And One For Dividend Growth

American States Water

Cincinnati Financial

Colgate-Palmolive

Dover

Emerson Electric

Genuine Parts

Lancaster Colony

Nordson

Northwest Natural Gas

Parker-Hannifin

24/7 Wall Street Insights Dividend Kings are companies with an unbroken track record of dividend increases spanning a minimum of 50 consecutive years.

These 13 Stocks Are True Dividend Kings

New five-year data reinforce long-term safety and efficacy of SPRAVATO® (esketamine) in patients with inadequate response to two or more oral antidepressants (treatment-resistant depression)   23 abstracts highlight data from Company's robust portfolio and pipeline, including clinical insights on major depressive disorder and the significant burden of anhedonia and insomnia symptoms Large real-world analysis highlights the link between reducing relapse and improving survival in schizophrenia TITUSVILLE, N.J. , Oct. 24, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announced today that 23 abstracts featuring new real-world and clinical trial data from across its neuropsychiatry portfolio and pipeline will be presented at the annual U.S. Psychiatric and Mental Health Congress (Psych Congress), taking place October 29 to November 2 in Boston, Massachusetts.

Johnson & Johnson highlights innovative neuropsychiatry portfolio and pipeline at Psych Congress

PHILADELPHIA, Oct. 23, 2024 (GLOBE NEWSWIRE) -- 2iG Solutions, Inc. (2iG or 2iG Solutions), provider of leading-edge data analytics and artificial intelligence (AI) reporting software, is pleased to announce that South Carolina-based premium finance company Johnson & Johnson Preferred Financing (JJPF), Inc. has successfully implemented the PFC Insight solution. Today, it is difficult for premium finance companies (PFC) to acquire intelligence to improve efficiency.

Johnson & Johnson Preferred Financing, Inc. Implements 2iG's PFC Insight

Lululemon Athletica

McDonald's

Disney

General Electric

These companies have faced setbacks, but I'm confident their stock prices will flourish once again.

7 Stocks I Have Faith In

Spravato, a depression treatment derived from club drug ketamine, was looking like a dud. Its recent success now shows a path forward for psychedelic-based medicines.

J&J's Ketamine-Derived Drug Is Taking Off

Investors looking for dividend stocks at reasonable valuations have come to the right place.

All It Takes Is $2,500 Invested in Each of These 3 High-Yield Dow Dividend Stocks to Help Generate Over $300 in Passive Income Per Year

J&J's Q3 2024 earnings beat expectations with $22.5B in revenue, driven by strong performances from Darzalex, STELARA, and MedTech, despite ongoing challenges. The company updated its full-year guidance, showing optimism despite headwinds like talc litigation and STELARA generic competition, maintaining strong cash flow and dividend payouts. New growth opportunities in oncology and MedTech segments, along with strategic acquisitions, are expected to offset potential declines in STELARA sales due to generics.

Johnson & Johnson: Q3 Earnings Highlights Resilience And New Growth

JNJ beats third-quarter estimates for both earnings and sales. Those who already own J&J's stock may stay invested.

J&J's Q3 Earnings & Sales Top: Time to Buy, Sell or Hold the Stock?

Pfizer

These stocks could deliver big over the long term.

3 No-Brainer Pharmaceutical Stocks to Buy With $500 Right Now

Johnson & Johnson's JNJ stock price advance has been reinvigorated. The stock price rally stalled a few years ago due to the COVID-19 bubble bursting and the divestiture of Kenvue KVUE, but those days are behind, and business growth is still ahead.

Johnson & Johnson Stock: Setting the Stage for 2025 Highs

Johnson & Johnson infused positive optimism after posting solid third-quarter 2024 earnings. A few analysts raised their target price on the stock.

ETFs in Focus Post JNJ Q3 Earnings Beat, Target Price Hike

Johnson & Johnson Q3 Earnings Review: Nicely Poised For Steady Growth (Upgrade)

Johnson & Johnson (NYSE: JNJ) recently reported its Q3 results, with revenues and earnings exceeding our estimates. The company reported revenue of $22.5 billion and adjusted earnings of $2.42 per share, compared to our estimates of $22.2 billion and $2.20, respectively.

What's Next For Johnson & Johnson Stock?

Johnson & Johnson's latest financial checkup shows it's still in excellent health.

This Magnificent Dividend Stock Is as Healthy as It Gets

Target

A dividend aristocrat is an S&P 500 stock that has raised its dividend annually for at least 25 years. These are typically the kinds of blue-chip stocks many fund managers with a dividend mandate tend to focus on, and for good reason. Finding companies that have been able to grow their earnings so reliably they can raise their distributions to shareholders over very long periods of time is certainly important.

News for Johnson & Johnson Stock (JNJ)